In vitro and in vivo evaluation of recombinant silk-elastinlike hydrogels for cancer gene therapy

2004 ◽  
Vol 94 (2-3) ◽  
pp. 433-445 ◽  
Author(s):  
Zaki Megeed ◽  
Mohamed Haider ◽  
Daqing Li ◽  
Bert W. O'Malley ◽  
Joseph Cappello ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
In Vivo Evaluation

In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy

2006 ◽  
Vol 113 (3) ◽  
pp. 255-260 ◽  
Author(s):  
Takehiro Serikawa ◽  
Akira Kikuchi ◽  
Susumu Sugaya ◽  
Norio Suzuki ◽  
Hiroshi Kikuchi ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cancer Gene Therapy ◽  
Cationic Liposomes ◽  
Cancer Gene ◽  
In Vivo Evaluation

scholarly journals LdrB Toxin with In Vitro and In Vivo Antitumor Activity as a Potential Tool for Cancer Gene Therapy

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1016 ◽  
Author(s):  
Yaiza Jiménez-Martínez ◽  
Carmen Griñán-Lisón ◽  
Hoda Khaldy ◽  
Ana Martín ◽  
Alba Cambrils ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Side Effects ◽  
Lethal Effect ◽  
Cancer Gene Therapy ◽  
Experimental Models ◽  
Cancer Gene ◽  
Inhibition Of Proliferation

Due to the high prevalence of cancer in recent years, it is necessary to develop new and more effective therapies that produce fewer side effects. Development of gene therapy for cancer based on the use of suicide genes that can damage the tumor cell, without requiring a prodrug for its lethal effect, is one of the recent foci of gene therapy strategies. We evaluated the cytotoxic impact of the LdrB toxin from Escherichia coli k12 as a possible tool for cancer gene therapy. For that, colorectal and breast cancer cells were transfected under the control of a TRE3G promoter inducible by doxycycline. Our results showed that ldrB gene expression induced a drastic inhibition of proliferation in vitro, in both 2D and 3D experimental models. Moreover, unlike conventional chemotherapy, the ldrB gene induced a severe loss of proliferation in vivo without any side effects in our animal model. This antitumor outcome was modulated by cell cycle arrest in the G0/G1 phase and apoptotic death. Scanning electronic microscopy demonstrates that the LdrB toxin conserves its pore-forming ability in HCT-116 cells as in E. coli k12. Taken together, our results provide, for the first time, a proof of concept of the antitumor capacity of the ldrB gene in colorectal and breast cancer.

Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo

2020 ◽  
Vol 36 (6) ◽  
Author(s):  
Zahra Salmasi ◽  
Maryam Hashemi ◽  
Elahe Mahdipour ◽  
Hossein Nourani ◽  
Khalil Abnous ◽  
...  
Keyword(s):  
Stem Cells ◽  
Gene Therapy ◽  
Mesenchymal Stem Cells ◽  
Cancer Gene Therapy ◽  
Cancer Gene

scholarly journals A TECNOLOGIA DE CRISPR-CAS9 NA TERAPIA GÊNICA DO CÂNCER DE PULMÃO

2019 ◽  
Vol 5 (13) ◽  
Author(s):  
Raphael Ladislau de Alcantara ◽  
Hellen Patricia Santos Lima ◽  
Gabriel de Oliveira Barbosa ◽  
Lucas Cândido Gonçalves ◽  
Adriana Priscila Lázaro da Silva ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Therapy ◽  
Adaptive Immunity ◽  
Cancer Gene Therapy ◽  
Cancer Gene ◽  
Terapia Génica

O presente estudo objetivou avaliar a possibilidade do CRISPR-Cas9 na terapia gênica do câncer de pulmão, por meio do conhecimento do mecanismo da CRISPR-Cas e da sua utilização no tratamento do câncer de pulmão. Trata-se de uma revisão de literatura de aspecto descritivo. Foram excluídas as publicações e artigos repetidos que não eram relacionadas ao tema, totalizando 22 referências e tendo como 41 referências que constituem o presente trabalho, retiradas no site da National Center for Biotecnology Information (NCBI), na base de dados PubMed. Foram utilizados os descritores: CRISPR/Cas9, Lung Cancer, Gene therapy, gene edition, adaptive immunity, após foram catalogadas e submetidas a análise. Estudos de artigos referentes à terapia gênica, através da utilização do CRISPR-Cas9, demonstraram diversas possibilidades de utilização do sistema para o tratamento de tumores, indicando um possível tratamento do câncer de pulmão pelo sistema CRISPR-Cas9, dependendo somente de pesquisa e estudos. O sistema CRISPR-Cas9 pode ser considerado a tecnologia do século, por proporcionar uma plataforma adequada para o desenvolvimento de pesquisas relacionadas aos adenocarcinomas em condições in vivo e in vitro e trazer diversas possibilidades para tratar o câncer de pulmão com base na terapia gênica.

Sign in / Sign up

Export Citation Format

Share Document